VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
EWTXEdgewise Therapeutics, Inc.
$36.81$4.0B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksEWTXPrice Target
EWTX logo

Edgewise Therapeutics, Inc. (EWTX) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 10 analysts

29.2% Below Target

EWTX trades 29.2% below Wall Street's consensus target of $47.56.

Current Price$36.81
Average Target$47.56
Target
Current
Low$25.00
Median$52.00
High$66.00

Analyst Target Range

Forward P/E—
PEG Ratio—
Implied Growth-18.5%
(Declining)
Analyst Spread86.2%
(Wide Disagreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$36.81
Consensus$47.56
High$66.00
Low$25.00

Consensus Scenario Assumptions

The base valuation assumes EWTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 10 published analyst recommendations for EWTX

8/10 analysts are bullish
+40
BearishBullish
Weighted analyst sentiment score based on 10 ratings
ConsensusBuy
Coverage10 Analysts
Net Score+40
Bull / Bear80% / 0%
Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
880%
Hold
220%
Sell
00%
Strong Sell
00%
Recommendation Mix80% Buy · 20% Hold · 0% Sell
Buy (8)Hold (2)Sell (0)

EWTX Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Edgewise Therapeutics, Inc. (EWTX) has a Wall Street consensus price target of $47.56, based on estimates from 10 covering analysts. With the stock currently trading at $36.81, this represents a potential upside of +29.2%. The company has a market capitalization of $3.96B.

Analyst price targets range from a low of $25.00 to a high of $66.00, representing a 86% spread in expectations. The median target of $52.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.

The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, EWTX trades at a trailing P/E of -22.6x. Analysts expect EPS to grow -18.5% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+53.4%
Industry Consensus
Avg Forward P/E
75.4x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
ACAD logo
ACADACADIA Pharmaceuticals Inc.
$3.7B$21.62$33.67
+55.7%
Buy55.6x37
KYMR logo
KYMRKymera Therapeutics, Inc.
$7.4B$90.43$112.60
+24.5%
Buy—26
CMPS logo
CMPSCOMPASS Pathways plc
$1.2B$12.53$18.57
+48.2%
Buy—13
IMVT logo
IMVTImmunovant, Inc.
$7.3B$35.34$45.00
+27.3%
Buy—23
ARQT logo
ARQTArcutis Biotherapeutics, Inc.
$3.3B$26.21$34.00
+29.7%
Buy131.6x12
PRAX logo
PRAXPraxis Precision Medicines, Inc.
$8.2B$282.31$584.00
+106.9%
Buy—16
MGTX logo
MGTXMeiraGTx Holdings plc
$1.0B$11.32$25.00
+120.8%
Buy—6
MDGL logo
MDGLMadrigal Pharmaceuticals, Inc.
$11.7B$505.75$710.22
+40.4%
Buy—23
URGN logo
URGNUroGen Pharma Ltd.
$1.6B$33.57$42.50
+26.6%
Buy—15
TMDX logo
TMDXTransMedics Group, Inc.
$2.7B$78.79$121.20
+53.8%
Buy38.9x12

EWTX — Frequently Asked Questions

Quick answers to the most common questions about buying EWTX stock.

What is the EWTX stock price target for 2026?

The consensus Wall Street price target for EWTX is $47.56, representing 29.2% upside from the current price of $36.81. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is EWTX a buy, sell, or hold?

EWTX has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $47.56 implies 29.2% upside from current levels.

Is EWTX stock overvalued or undervalued?

EWTX's current price is $36.81 with a consensus target of $47.56 (29.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.

How high can EWTX stock go?

The most bullish Wall Street analyst has a price target of $66 for EWTX, while the most conservative target is $25. The consensus of $47.56 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover EWTX stock?

EWTX is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the EWTX stock forecast?

The 12-month EWTX stock forecast based on 10 Wall Street analysts shows a consensus price target of $47.56, with estimates ranging from $25 (bear case) to $66 (bull case). The median consensus rating is "Buy".

Should I buy EWTX stock?

Wall Street analysts are very optimistic on EWTX, with a "Buy" consensus rating and $47.56 price target (29.2% upside). 8 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do EWTX price targets vary so much?

EWTX analyst price targets range from $25 to $66, a 86% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $47.56 consensus represents the middle ground.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare